Inozyme Pharma Inc (NASDAQ: INZY)’s stock price has dropped by -4.80 in relation to previous closing price of 1.03. Nevertheless, the company has seen a loss of -1.66% in its stock price over the last five trading days. globenewswire.com reported 2025-04-10 that – Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious cardiovascular and musculoskeletal complications – – Findings highlight the urgent need for early and improved diagnosis, care and treatments that address the long-term systemic effects of ENPP1 Deficiency – BOSTON, April 10, 2025 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the publication of a paper titled, “Phenotypic characterization of ENPP1 deficiency: generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2” in JBMR Plus that characterizes the severity and progression of ENPP1 Deficiency. Inozyme collaborated with leading disease experts Carlos Ferreira, M.D.
Is It Worth Investing in Inozyme Pharma Inc (NASDAQ: INZY) Right Now?
Company’s 36-month beta value is 1.26.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INZY is 43.53M, and currently, short sellers hold a 9.66% ratio of that floaft. The average trading volume of INZY on April 24, 2025 was 569.10K shares.
INZY’s Market Performance
INZY’s stock has seen a -1.66% decrease for the week, with a -2.91% drop in the past month and a -24.57% fall in the past quarter. The volatility ratio for the week is 10.30%, and the volatility levels for the past 30 days are at 12.10% for Inozyme Pharma Inc The simple moving average for the past 20 days is 5.74% for INZY’s stock, with a -70.09% simple moving average for the past 200 days.
Analysts’ Opinion of INZY
Many brokerage firms have already submitted their reports for INZY stocks, with Raymond James repeating the rating for INZY by listing it as a “Outperform.” The predicted price for INZY in the upcoming period, according to Raymond James is $26 based on the research report published on December 12, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see INZY reach a price target of $16. The rating they have provided for INZY stocks is “Buy” according to the report published on September 12th, 2024.
Jefferies gave a rating of “Buy” to INZY, setting the target price at $17 in the report published on August 13th of the previous year.
INZY Trading at -7.45% from the 50-Day Moving Average
After a stumble in the market that brought INZY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.29% of loss for the given period.
Volatility was left at 12.10%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares surge +0.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.96% lower at present.
During the last 5 trading sessions, INZY fell by -1.66%, which changed the moving average for the period of 200-days by -78.16% in comparison to the 20-day moving average, which settled at $0.9274. In addition, Inozyme Pharma Inc saw -64.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INZY starting from Treco Douglas A, who sale 8,819 shares at the price of $0.89 back on Apr 02 ’25. After this action, Treco Douglas A now owns 41,046 shares of Inozyme Pharma Inc, valued at $7,849 using the latest closing price.
Stock Fundamentals for INZY
The total capital return value is set at -1.17. Equity return is now at value -102.90, with -62.97 for asset returns.
Based on Inozyme Pharma Inc (INZY), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -1.96. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is -18.72.
Currently, EBITDA for the company is -104.03 million with net debt to EBITDA at -0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.56.
Conclusion
In a nutshell, Inozyme Pharma Inc (INZY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
